Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$70.95 +0.4%	$64.55	$47.86 ▼ $107.37	$3.90B	0.28	605,028 shs	534,969 shs
DYN Dyne Therapeutics	$9.40 +0.8%	$11.24	$6.36 ▼ $47.45	$1.06B	1.08	1.91 million shs	2.44 million shs
PTCT PTC Therapeutics	$48.53 +0.8%	$48.76	$29.02 ▼ $58.38	$3.82B	0.5	876,179 shs	552,502 shs
RNA Avidity Biosciences	$34.04 +1.5%	$30.86	$21.51 ▼ $56.00	$4.04B	0.91	1.41 million shs	2.78 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	+3.74%	+2.46%	+10.31%	+14.00%	+7.25%
DYN Dyne Therapeutics	+12.68%	+5.07%	-32.49%	+14.20%	-78.87%
PTCT PTC Therapeutics	+0.82%	-1.23%	-7.19%	+1.58%	+40.88%
RNA Avidity Biosciences	+5.77%	+7.23%	+12.52%	+25.77%	-28.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACLX Arcellx	2.5183 of 5 stars	3.5	2.0	0.0	3.1	2.5	0.0
DYN Dyne Therapeutics	3.894 of 5 stars	4.5	3.0	0.0	3.0	4.2	0.0
PTCT PTC Therapeutics	4.4777 of 5 stars	4.3	1.0	4.4	3.1	0.8	1.3
RNA Avidity Biosciences	2.1816 of 5 stars	4.5	0.0	0.0	2.7	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	3.07	Buy	$111.23	56.77% Upside
DYN Dyne Therapeutics	3.00	Buy	$40.63	332.18% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	33.94% Upside
RNA Avidity Biosciences	3.06	Buy	$66.35	94.93% Upside

Current Analyst Ratings Breakdown

Latest DYN, RNA, PTCT, and ACLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
7/11/2025	RNA Avidity Biosciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00
7/11/2025	DYN Dyne Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/10/2025	RNA Avidity Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$55.00
6/27/2025	RNA Avidity Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$96.00
6/26/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/25/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2025	DYN Dyne Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00
6/24/2025	RNA Avidity Biosciences	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
6/18/2025	DYN Dyne Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/18/2025	DYN Dyne Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$46.00 ➝ $32.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$107.94M	36.22	N/A	N/A	$8.41 per share	8.44
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.19 per share	N/A
PTCT PTC Therapeutics	$806.78M	4.77	N/A	N/A	($14.24) per share	-3.41
RNA Avidity Biosciences	$10.90M	376.38	N/A	N/A	$11.94 per share	2.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$107.35M	-$2.99	N/A	N/A	N/A	-211.46%	-35.27%	-22.73%	8/14/2025 (Estimated)
DYN Dyne Therapeutics	-$317.42M	-$3.59	N/A	N/A	N/A	N/A	-52.83%	-48.84%	8/11/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	7.45	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	8/8/2025 (Estimated)

Latest DYN, RNA, PTCT, and ACLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACLX Arcellx	-$1.03	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	PTCT PTC Therapeutics	-$1.07	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	RNA Avidity Biosciences	-$0.93	N/A	N/A	N/A	$1.61 million	N/A
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/8/2025	Q1 2025	DYN Dyne Therapeutics	-$0.88	-$1.05	-$0.17	-$1.05	N/A	N/A
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	4.93	4.93
DYN Dyne Therapeutics	N/A	20.35	20.35
PTCT PTC Therapeutics	N/A	3.89	3.85
RNA Avidity Biosciences	N/A	16.91	16.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
DYN Dyne Therapeutics	96.68%
PTCT PTC Therapeutics	N/A
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
DYN Dyne Therapeutics	14.14%
PTCT PTC Therapeutics	5.50%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	55.11 million	50.51 million	Optionable
DYN Dyne Therapeutics	100	113.67 million	97.59 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
RNA Avidity Biosciences	190	120.52 million	115.90 million	Optionable

DYN, RNA, PTCT, and ACLX Headlines

Recent News About These Companies

Avidity Biosciences: Three Accelerated Approval Shots Feels Excessive

July 14 at 4:24 PM | seekingalpha.com

Avidity Biosciences (NASDAQ:RNA) Shares Gap Up - Here's Why

July 14 at 11:11 AM | marketbeat.com

Avidity Biosciences price target raised to $70 from $60 at Evercore ISI

July 12, 2025 | msn.com

Alps Advisors Inc. Has $2.58 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

July 12, 2025 | marketbeat.com

The Goldman Sachs Group Upgrades Avidity Biosciences (NASDAQ:RNA) to Buy

July 12, 2025 | americanbankingnews.com

Avidity Biosciences, Inc. (RNA) Balance Sheet - Yahoo Finance

July 11, 2025 | finance.yahoo.com

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at The Goldman Sachs Group

July 10, 2025 | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

July 6, 2025 | marketbeat.com

Avidity Biosciences, Inc. (RNA) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

7RNA : Expert Outlook: Avidity Biosciences Through The Eyes...

June 27, 2025 | benzinga.com

Avidity Biosciences (NASDAQ:RNA) Receives "Overweight" Rating from Cantor Fitzgerald

June 27, 2025 | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA therapies stock faces pivotal year

June 26, 2025 | investing.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from Analysts

June 26, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Earns Outperform Rating from Analysts at Sanford C. Bernstein

June 24, 2025 | marketbeat.com

Avidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advance

June 24, 2025 | investing.com

SG Americas Securities LLC Takes $516,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 23, 2025 | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027

June 20, 2025 | investing.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $27,548.64 in Stock

June 19, 2025 | insidertrades.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Kathleen P. Gallagher Sells 911 Shares

June 18, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Trading Up 4.1% - Here's Why

June 17, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated at Wolfe Research

June 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated

DYN, RNA, PTCT, and ACLX Company Descriptions

Arcellx NASDAQ:ACLX

$70.95 +0.25 (+0.35%)

Closing price 04:00 PM Eastern

Extended Trading

$70.94 -0.01 (-0.01%)

As of 05:11 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Dyne Therapeutics NASDAQ:DYN

$9.40 +0.07 (+0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$9.32 -0.08 (-0.80%)

As of 07:58 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

PTC Therapeutics NASDAQ:PTCT

$48.53 +0.39 (+0.81%)

Closing price 04:00 PM Eastern

Extended Trading

$48.54 +0.02 (+0.03%)

As of 07:56 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Avidity Biosciences NASDAQ:RNA

$34.04 +0.51 (+1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$34.22 +0.19 (+0.54%)

As of 07:59 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time